Posted on June 20, 2024

DALLAS – June 18, 2024 – A statistical tool designed to analyze 11 characteristics of postmortem brains reliably diagnosed a common neurodegenerative disease known as essential tremor (ET), a study led by researchers at UT Southwestern Medical Center and Columbia University shows. Their findings, 20 years in the making and published in the Annals of Clinical and Translational Neurology, […]

Posted on June 10, 2024

SAN MATEO, Calif., June 10, 2024 /PRNewswire/ — Cala, the bioelectronic medicine leader, reached a major milestone: a positive Medicare Local Coverage Determination for the Cala TAPS (Transcutaneous Afferent Patterned Stimulation) Therapy for essential tremor (ET) from the Centers for Medicare & Medicaid Services (CMS):  External Upper Limb Tremor Stimulator Therapy L39591. Medicare beneficiaries who qualify under the new coverage guidelines now […]

Posted on March 7, 2024

Dementia may be three times more common among people with essential tremor, a movement disorder that causes involuntary shaking, than the general population, according to research released today, March 6, 2024. The study will be presented at the American Academy of Neurology’s 76th Annual Meeting taking place April 13–18, 2024, in person in Denver and online.

CAMBRIDGE, Mass.–(BUSINESS WIRE)–A group of leading scientists, doctors and entrepreneurs are unveiling a first-of-its-kind wearable neurotechnology platform that uses proprietary algorithms and artificial intelligence (AI) to improve health through noninvasive, proactive brainwave stimulation, without the side effects of pharmaceuticals. Elemind, the new AI-enhanced neurotech health company, emerged from stealth today, closing a $12M Seed round to […]

ABBOTT PARK, Ill., Jan. 25, 2024 /PRNewswire/ — Abbott (NYSE: ABT) announced today that it received approval from the U.S. Food and Drug Administration (FDA) to launch the Liberta RC™ DBS system, the world’s smallest rechargeable deep brain stimulation (DBS) device with remote programming, to treat people living with movement disorders.1+ The Liberta RC DBS system also requires […]

HAIFA, Israel and MIAMI, Jan. 24, 2024 /PRNewswire/ — Insightec, a global healthcare company dedicated to using acoustic energy to transform patient care, today announced that effective immediately, 9.5 million US military members and their covered dependents, covered by Tricare are now eligible for coverage reimbursement for focused ultrasound treatment for essential tremor.

MIAMI, Oct. 16, 2023 /PRNewswire/ — Insightec, a global healthcare company dedicated to using acoustic energy to transform patient care, today announced that it has been awarded the 2023 BioFlorida David J. Gury Company of the Year Award for distinguished achievement in focused ultrasound technology and contributions to Florida’s life sciences industry. The award was presented at BioFlorida’s 26th Annual […]

Posted on June 15, 2023

June 15, 2023 – By Gina Shaw, Neurology Today The incidence of Parkinson’s disease (PD) in patients with essential tremor (ET) is significantly higher than that reported in historical population-based control groups across numerous countries, according to a prospective longitudinal study published online May 10 in Neurology: Clinical Practice. The findings are consistent with those of […]

Posted on June 14, 2023

June 14, 2023 – Cala announced today that it launched its next-generation Cala kIQ system, a wearable device that delivers therapy for neurological disorders. The San Mateo, California-based company develops the Cala Trio device for transcutaneous afferent patterned stimulation (TAPS) therapy. Cala designed the Trio device for treating tremor. Its kIQ system delivers therapy for action […]

Posted on June 12, 2023

BOSTON, June 09, 2023 (GLOBE NEWSWIRE) — Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a clinical-stage biopharmaceutical company translating genetic insights into the development of therapies for central nervous system (CNS) disorders characterized by neuronal excitation-inhibition imbalance, today announced the outcomes from a recent end-of-Phase 2 meeting with the U. S. Food and Drug Administration (FDA) […]